Unknown

Dataset Information

0

The emerging role of antibody-drug conjugates in urothelial carcinoma.


ABSTRACT:

Introduction

In December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic urothelial carcinoma. Antibody-drug conjugates represent a new therapeutic modality in urothelial cancer; and beyond nectin-4, agents targeting Trop-2, HER2, and EpCAM are also in clinical development.

Areas covered

This review outlines the biologic rationale and the clinical development of novel antibody-drug conjugates for the treatment of urothelial cancer across the spectrum of disease from non-muscle-invasive bladder cancer through treatment-refractory metastatic disease.

Expert opinion

The high response rates observed with enfortumab vedotin - both as monotherapy and in combination with checkpoint blockade immunotherapy - suggest this and other antibody-drug conjugates may have efficacy similar to or even exceeding that of traditional cytotoxic chemotherapy. Ongoing clinical development of antibody-drug conjugates in urothelial cancer will address the optimal combination or sequencing strategy with anti-PD-1/L1 immunotherapy and platinum-based chemotherapy.

SUBMITTER: Lattanzi M 

PROVIDER: S-EPMC7545404 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9846350 | biostudies-literature
| S-EPMC8224177 | biostudies-literature
| S-EPMC4815767 | biostudies-literature
| S-EPMC8833781 | biostudies-literature
| S-EPMC9402760 | biostudies-literature
| S-EPMC6482108 | biostudies-literature
| S-EPMC9603928 | biostudies-literature
| S-EPMC10418918 | biostudies-literature
| S-EPMC7356544 | biostudies-literature
| S-EPMC11199396 | biostudies-literature